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A B S T R A C T
Bile acids have been implicated in the development of gastrointestinal malignancies. Both the speciﬁc nature of
individual bile acids and their concentration appear key factors in the carcinogenic potency of bile. Using liquid
chromatography mass spectrometry (LC–MS) we performed quantitative proﬁling of bile extracted directly from
the common bile duct in 30 patients (15 patients with pancreatic cancer and 15 patients with benign disease).
Separation and detection of bile acids was performed using a 1.7 μm particle size reversed-phase C18 LC column
at a ﬂow rate of 200 μL/min with negative electrospray ionization MS. A signiﬁcant diﬀerence (p = 0.018) was
seen in the concentration of unconjugated cholic acid in the malignant group (0.643 mmol/L) compared to the
benign group (0.022 mmol/L), with an overall signiﬁcant diﬀerence (p = 0.04) seen in the level of total un-
conjugated bile acids in the malignant group (1.816 mmol/L) compared to the benign group (0.069 mmol/L).
This ﬁnding may oﬀer the possibility of both understanding the biology of cancer development in the pancreas,
as well as oﬀering a potential diagnostic avenue to explore. However, a larger study is necessary to conﬁrm the
alterations in bile acid proﬁles reported here and explore factors such as diet and microbial populations on the
bile acid proﬁles of these patient groups.
1. Introduction
In the United Kingdom 21 people are diagnosed with ductal ade-
nocarcinoma of the pancreas each day, with only 3% of people sur-
viving 5 years after diagnosis [1]. Currently, only surgery oﬀers the
possibility of cure [2]. A better understanding of the pathogenesis of
this disease is required in order that prevention, early detection and
eﬀective treatments are realised. Bile acids are a normal component of
the gastrointestinal (GI) tract, where they enable absorption of lipids,
cholesterol and fat-soluble vitamins. Despite this, there is accumulating
evidence that implicates bile acids in the development of GI malig-
nancies including oesphageal, stomach and colon cancers [3,4]. The
majority of pancreatic cancers occur at the head of the pancreas, which
is in close proximity to the bile duct raising the possibility that bile
acids have a role in the pathogenesis of this cancer. In animal studies,
where surgical procedures have been undertaken to alter the anatomy
causing bile to reﬂux into the pancreatic duct, an increased incidence of
pancreatic malignancy is seen [5].
In the human body, bile acid composition is regulated by synthesis,
mostly in the liver, and through the enterohepatic circulation. So called
“primary bile acids” (cholic acid, chenodeoxycholic acid) are con-
jugated to the amino acids glycine and taurine in the liver, prior to
storage in the gallbladder and release ﬁrst into the bile duct, and then
duodenum. Greater than 95% of primary bile acids are reabsorbed in
the terminal ileum. In the colon, primary bile acids are deconjugated
and converted to so called “secondary bile acids” (e.g. deoxycholic acid,
ursodeoxycholic acid and lithocholic acid) by bacterial ﬂora. The sec-
ondary bile acids deoxycholic acid and ursodeoxycholic acid are partly
absorbed in the colon and enter the enterohepatic circulation, whilst
lithocholic acid is largely insoluble [6,7]. The structure of bile acids
allows them to act as detergents, disrupting the lipid bi-layer of cells,
potentially allowing carcinogenic substances to enter the cell [4,8].
Secondary bile acids have been speciﬁcally shown to have carcinogenic
properties. Deoxycholic acid has been shown to generate reactive
oxygen species which can cause apoptosis of cells [9]. Additionally, in
animal studies a diet high in the primary bile acid cholic acid leads to
an increased resistance to apoptosis of colon crypt cells [10]. Bernstein
et al. hypothesize that this favours selection of apoptosis resistant cells,
predisposing to the development of malignancy [3]. Nagathihalli et al.
have shown deoxycholic acid to activate EGFR signaling, by cleavage of
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the protein amphiregulin, leading to cell proliferation [11]. Cycloox-
ygenase-2 (COX-2) and its enzymatic product prostaglandin E2 (PGE2)
have been implicated in tumour formation [12,13]. Tucker et al. de-
monstrated upregulation of COX-2 in human pancreatic cell lines when
treated with chenodeoxycholic and deoxycholic acid, an increase in
PGE2 was also observed [14].
Both the speciﬁc nature of individual bile acids and their con-
centration appear key factors in the carcinogenic potency of bile. Liquid
chromatography-mass spectrometry (LC–MS) is an established tech-
nique to accurately characterise and measure individual bile acids in
biological ﬂuids [15]. The aim of this study is to analyse bile acid
proﬁles using LC–MS, by extracting bile directly from the common bile
duct of patients with pancreatic cancer and benign disease.
2. Materials and methods
2.1. Patients
The study was divided into two groups of patients attending for
upper gastrointestinal surgery at Morriston Hospital, Swansea. The ﬁrst
group of patients had a diagnosis of cholecystitis, benign disease, and
underwent cholecystectomy surgery. This group consisted of 15 pa-
tients, 12 female and 3 male. The second group of patients underwent
pyloris preserving pancreaticoduodenectomy and were diagnosed with
adenocarcinoma of the pancreas, after histopathological examination
(Table 1). This group consisted of 15 patients, 6 female and 9 male. In
both groups the bile sample was obtained by direct extraction from the
common bile duct during surgery. In patients undergoing pyloris pre-
serving pancreaticoduodenectomy pancreatic ﬂuid was also collected
directly from the pancreatic duct. All patients had been fasted from
midnight. No special dietary instructions were given to either group.
Prior to surgery, serum liver function tests (alkaline phosphatase (ALP),
alkaline transferase (ALT) and bilirubin) of patients were also carried
out.
2.2. Ethical aspects
Informed consent for extraction, storage and analysis of biliary ﬂuid
was obtained from all 30 patients undergoing elective surgery, with
ethical permission obtained from South West Wales Research and Ethics
Committee (10/WMW02/34).
2.3. Reagents
Bile acid standards (cholic acid and deoxycholic acid) were obtained
from Sigma Aldrich (Dorset, UK) and were at least 98% pure. The in-
ternal standard, 3α,12α-dihydroxy-23-nor-5β-cholanoic acid, was ob-
tained from Steraloids (Newport, RI, USA). Other bile acid standards
were from previous studies [15]. HPLC grade solvents and reagents
were from Fisher Scientiﬁc (Loughborough, UK) or Sigma Aldrich.
2.4. Preparation of internal standards
Taurine conjugated 3α,12α-dihydroxy-23-nor-5β-cholanoic acid
and glycine conjugated 3α,12α-dihydroxy-23-nor-5β-cholanoic acid
were synthesized as described previously for use as internal standards
[16]. LC–MS relative response factors were calculated for accurately
prepared solutions of unconjugated, glycine conjugated and taurine
conjugated bile acid standards.
2.5. Extraction for bile acid analysis
Bile (1 μL) was added to 1 mL of 50% HPLC grade methanol and
heated at 60 °C for 30 min. The mixture was centrifuged at 14,000g for
30 min at 4 °C. The supernatant was removed and stored at −80 °C.
3α,12α-Dihydroxy-23-nor-5β-cholanoic acid as well as the corre-
sponding glycine and taurine conjugates were added as internal stan-
dards. The resulting mixture was diluted by a factor of 10,000 prior to
analysis by LC–MS.
2.6. LC–MS analysis on the LTQ-Orbitrap
Separation of bile acids was performed on an Ultimate 3000 HPLC
System (Dionex, now Thermo Fisher, Hemel Hempstead, UK) using a
Phenomonex Kinetex C18 column (50 × 2.1 mm, 1.7 μm particle size,
Macclesﬁeld, UK). Mobile phase A consisted of 33.3% methanol, 16.7%
acetonitrile, 0.1% formic acid. Mobile phase B consisted of 63.3%
methanol, 31.7% acetonitrile, 0.1% formic acid. The ﬂow rate was
200 μL/min. The gradient started at 20% mobile phase B for 1 min
before rising to 80% mobile phase B over the following 7 min. After a
further 5 min, the gradient returned to 20% B over 6 s before re-equi-
libration for 3 min 54 s to give a total run time of 17 min. The eluent
was directed to the atmospheric pressure ionization (API) source of an
LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher) operating in
negative ion electrospray mode. 50 μL of the diluted sample was in-
jected onto the column and a full mass spectrum was recorded in the
Orbitrap over the m/z range 350–700 at 120,000 resolution (at m/z
400, FWHM deﬁnition). The Orbitrap was calibrated externally prior to
each analytical session and the mass error was less than 5 ppm.
2.7. Statistical analysis
Analysis was performed using SPSS for Windows. No assumptions of
normality were made and the non-parametric Mann Whitney U-test was
used to compare malignant to benign groups. A p-value<0.05 was
considered statistically signiﬁcant.
3. Results
Bile from 30 patients was analysed. 15 patients had a diagnosis of
cholecystitis, the remaining 15 patients had a diagnosis of adeno-
carcinoma of the pancreas (Table 1). Analysis of serum liver function
tests showed no signiﬁcant diﬀerence between the levels of ALP or
bilirubin in patient serum when comparing the benign and malignant
groups (Table 2).
Table 1
Demographic and histopathological characteristics of patients.
Disease Cholecystitis Adenocarcinoma of the pancreas
Sex (males/females) 3/12 9/6
Age (years) 50 (17–85) 62 (52–75)
Staging
Adenocarcinoma pT1 N0 0 1
Adenocarcinoma pT2 N1 0 1
Adenocarcinoma pT3 N1 0 9
Adenocarcinoma pT3 N0 0 4
Table 2
Serum biochemical parameters of patients, p < 0.05 is signiﬁcant.
Cholecystitis Adenocarcinoma of the
pancreas
p-value
Total serum bilirubin
(μmol/L) (prior to
surgery)
13.9 (3–50) 15.3 (4–95) 0.280
Alkaline phosphatase
(ALP) (U/L) (prior to
surgery)
146.9 (70–782) 108 (53–312) 0.497
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Bile samples were analysed by LC–MS in the negative ion mode. The
carboxylic, or sulphonic, acid moiety of bile acids results in the for-
mation of intense [M-H]− ions that are readily detected. To obtain
quantitative data we added a commercially available unnatural trun-
cated bile acid (3α,12α-dihydroxy-23-nor-5β-cholanoic acid) as an in-
ternal standard. This compound has a similar structure to deoxycholic
acid but with one less methylene group in the side chain and therefore
has similar physicochemical properties. In addition, we synthesized the
corresponding glycine and taurine conjugates of 3α,12α-dihydroxy-23-
nor-5β-cholanoic acid for use as internal standards.
Individual and total bile acids in the benign group were compared to
the malignant group (Fig. 1, Table 3). A trend towards a higher con-
centration of individual unconjugated bile acids was seen in the ma-
lignant group compared to the benign group (Fig. 2). A signiﬁcant
diﬀerence (p = 0.018) was seen in the concentration of unconjugated
cholic acid in the malignant group (0.643 mmol/L) compared to the
benign group (0.022 mmol/L), with an overall signiﬁcant diﬀerence
(p = 0.04) seen in the level of total unconjugated bile acids in the
malignant group (1.816 mmol/L) compared to the benign group
(0.069 mmol/L). No signiﬁcant diﬀerence was seen when comparing
the concentrations of the conjugated bile acids. Sulphate, glucuronide
and glucoside derivatives of the bile acids were not detected in either
benign or malignant samples. Bile acids were not detected in the pan-
creatic ﬂuid collected.
A limited bivariate correlation was performed between bile acid
concentrations and serum biochemical tests (Table 4). In the malignant
group, no signiﬁcant correlation was seen between serum bilirubin and
unconjugated cholic acid or between serum bilirubin and total un-
conjugated bile acid. Interestingly, a signiﬁcant correlation was seen in
the benign group between serum ALP and unconjugated cholic acid
(p < 0.01) and serum ALP and total unconjugated bile acid
(p < 0.01).
4. Discussion
Previous studies have linked high physiological concentrations of
bile acids and of speciﬁc bile acids to GI malignancies [3,17]. In this
study we compared the composition of bile from patients with chole-
cystitis and adenocarcinoma of the pancreas. Each sample was collected
directly from the common bile duct during the patient’s planned sur-
gery. There was general agreement between concentrations of bile acids
measured with those previously reported [15]. A signiﬁcant diﬀerence
was found between the benign and malignant groups in the con-
centration of unconjugated cholic acid and in the total unconjugated
bile acids (Fig. 1, Table 3). Higher concentrations of the other un-
conjugated bile acids were also seen in the malignant group compared
to the benign, however these were not signiﬁcant and may reﬂect the
relatively low numbers of patients involved. These results are en-
couraging in terms of conducting a future analysis on a larger group of
patients.
We report here results of a direct comparison between bile acid
proﬁles of patients with adenocarcinoma at the head of the pancreas
and benign disease. Wen et al. used nuclear magnetic resonance to
compare bile from patients with biliary tract cancer and benign disease
[18]. Applying orthogonal partial least square discriminant analysis
(OPLS-DA), results showed good distinction between cancer and benign
groups, the OPLS-DA model was found to be more sensitive and speciﬁc
*
*
Fig. 1. Comparison of biliary unconjugated bile acid concentrations (mmol/L) from be-
nign and malignant samples. Standard error of the mean indicated by the error bars. CA,
cholic acid, UDCA, urosodeoxycholic acid; CDCA, chenodeoxycholic acid; DCA, deoxy-
cholic acid. *, p < 0.05.
Table 3
Comparison of concentrations of isolated bile acids in benign and malignant groups following LC–MS, p< 0.05 is signiﬁcant.
Bile acid Mean concentration (mmol/L) Standard error of the mean (mmol/L) p-value
Benign Malignant Benign Malignant
Cholic acid 0.022 0.643 0.012 0.277 0.018
Ursodeoxycholic acid 0.010 0.038 0.003 0.019 0.289
Chenodeoxycholic acid 0.010 0.493 0.010 0.370 0.114
Deoxycholic acid 0.027 0.636 0.027 0.417 0.126
Lithocholic acid 0.000 0.000 N/A N/A N/A
Total unconjugated bile acids 0.069 1.816 0.047 0.950 0.040
Glychocholic acid 32.831 44.361 5.837 6.808 0.215
Glycoursodeoxycholic acid 3.177 3.206 1.192 1.387 0.741
Glycochenodeoxycholic acid 28.405 34.324 4.962 4.399 0.407
Glycodeoxycholic acid 27.169 29.101 7.127 4.740 0.453
Glycolithocholic acid 1.418 1.433 0.531 0.601 1
Total glycine conjugative bile acids 94.526 113.345 18.374 13.557 0.215
Taurocholic acid 12.718 20.127 2.719 6.454 0.342
Tauroursodeoxycholic acid 0.578 0.388 0.233 0.103 0.711
Taurochenodeoxycholic acid 12.809 14.979 3.788 3.866 0.430
Taurodeoxycholic acid 9.036 9.524 3.011 2.167 0.430
Taurolithocholic acid 0.465 0.566 0.133 0.182 0.968
Total taurine conjugated bile acids 35.935 45.883 9.368 12.354 0.384
Total bile acids 130.531 161.044 25.975 24.814 0.197
p-values shown in bold are considered statistically signiﬁcant.
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compared to conventional biomarkers. Both Xiao et al. and Zhang et al.
have used LC–MS in an attempt to identify biomarkers in hepatocellular
carcinoma (HCC) [19,20]. Interestingly, Xiao et al. showed serum gly-
cocholic acid (GCA) to be reduced in patients with HCC compared to
those with liver cirrhosis, whilst Zhang et al. found GCA to be elevated
in the urine of patients with HCC compared to healthy controls [19,20].
Using high performance liquid chromatography (HPLC) Jusakul et al.
compared biliary bile acid proﬁles taken from patients undergoing liver
resection for malignant disease and benign biliary disease and showed
the concentration of cholic acid to be signiﬁcantly higher in cho-
langiocarcinoma and HCC patients compared to the benign group [21].
Jusakul et al. also demonstrated a signiﬁcant correlation between
serum bilirubin and total cholic acid, concluding that bile duct ob-
struction may promote bile acid synthesis in the liver, catalyzing
malignant growth [21]. However, unlike Jusakul et al. we found no
correlation between serum biochemistry and bile acids in the malignant
group.
The biological mechanism to explain the diﬀerences in the bile acid
proﬁles is uncertain. One explanation for the increased concentration of
unconjugated bile acids extracted from the common bile duct (CBD) in
the malignant group is the presence of bacteria in and around the duct
producing hydroxylases in the CBD. Research conducted on CBD stones
may oﬀer an explanation. CBD stones prevent the ﬂow of bile into the
duodenum, leading to bile stasis which has been shown to cause bac-
terial growth [22]. As with a CBD stone, a tumour at the head of the
pancreas can also cause bile duct obstruction.
No bile acids were detected upon analysis of pancreatic ﬂuid,
therefore the hypothesis that bile acids reﬂux to the pancreatic duct and
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Fig. 2. Reconstructed ion chromatograms (±5 ppm)
showing [M−H]− ions of ursodeoxycholic acid (m/z
391.2854, Rt 5.9 min), cholic acid (m/z 407.2803, Rt
7.0 min), chenodeoxycholic acid (m/z 391.2854, Rt
8.7) and deoxycholic acid (m/z 391.2854, Rt 8.9)
from a patient with (A) adenocarcinoma and (B) with
cholecystitis. The peaks corresponding to cholic acid
are in red. Rt, retention time.
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lead to pancreatic inﬂammation has not been proven. In a review by
Lerch et al., one argument against reﬂux is pressure in the pancreatic
duct is generally quoted as being much higher than in the CBD [23].
Interestingly, a study by Csendes et al. agreed with this ﬁnding [24],
however, the authors reported that one limitation of their study was the
diﬀerence in the diameters of the pancreatic duct and CBD which could
eﬀect the pressures recorded when using the same size catheter probe.
Csendes’ research highlights the diﬃculty in analysing physiological
systems, and reﬂects the ongoing debate in the literature regarding the
role of bile acids in pancreatic disease pathophysiology. Bile acids have
been shown to have a direct aﬀect on acinar cells initiating an in-
ﬂammatory process, with membrane co-transporters for bile acids
found on the luminal and basolateral surface of acinar cells [25]. Al-
though all patients in this study were fasted overnight, one factor not
taken into account was patient diet. High fat diets have been shown to
increase the concentration of bile acid in faeces [26]. Epidemiological
research has shown an increased incidence of colorectal cancer in po-
pulations with an increased faecal bile acid concentration [27,28].
Deoxycholic acid has been implicated in the development of colorectal
cancer [27,29]. In our study, although an increased concentration of
unconjugated deoxycholic acid was seen in the malignant group it was
not signiﬁcant.
Having found a signiﬁcant diﬀerence in bile acid proﬁles in benign
and malignant groups one clinical application from this study is the
potential development of a biomarker. New biomarkers are integral to
improving survival in pancreatic cancer through early diagnosis and in
the monitoring of disease activity. Exploring whether the results found
here could be replicated in serum samples would be therefore of great
interest [30].
5. Conclusion
This study has shown a signiﬁcant increase in both unconjugated
cholic acid and total unconjugated bile acids when comparing patients
with adenocarcinoma of the pancreas to those with benign disease. The
mechanism by which this occurs is unclear. A drawback of this study is
the relatively low samples numbers. A larger study is necessary to
conﬁrm the alterations in bile acid proﬁles, particularly exploring the
trend towards higher concentrations seen in individual unconjugated
bile acids from the malignant group. In addition, incorporating the
inﬂuence of factors such as diet and microbial populations on the bile
acid proﬁles in patients would be of beneﬁt in analysing future results.
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